Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panax Notoginseng Saponins in Hypertensive Cerebral Hemorrhage
NCT02999048Phase 4Completed
- Sponsor
- Jingzhou First People's Hospital
- Start
- May 2014
- Primary completion
- May 2016
- Modality
- HM (Herbal Medicine)
01
Overview
Phase 4, randomised trial of panax notoginseng extract in intraparenchymal hematoma (IPH) (2 arms), sponsored by Jingzhou First People's Hospital. Primary endpoints: Hematoma volume at 14 days, National Institutes of Health Stroke Scale at 14 days and 1 more. Started May 2014; status: completed.
02
Drugs
panax notoginseng extract
03
Conditions
intraparenchymal hematoma (IPH)
Beyond the preview
Go deeper on NCT02999048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999048.